Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linvoseltamab + lenalidomide
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Linvoseltamab + lenalidomide** is an investigational combination therapy for multiple myeloma. Linvoseltamab is a bispecific monoclonal antibody designed to target both B-cell maturation antigen (BCMA) on malignant plasma cells and CD3 on T cells, thereby engaging and redirecting T cells to kill myeloma cells. Lenalidomide is an established immunomodulatory drug (IMiD) that modulates substrate specificity of the CRL4^CRBN^ E3 ubiquitin ligase, leading to degradation of transcription factors (IKZF1, IKZF3) critical for myeloma cell survival, and has direct antitumor, immunostimulatory, and anti-angiogenic properties. The combination is being evaluated clinically to augment depth of response and durability of minimal residual disease negativity in multiple myeloma patients. Linvoseltamab is being developed by Regeneron, while lenalidomide is marketed by Bristol Myers Squibb[1][2][3][4][5].
- Other names
- linvoseltamab + lenalidomide
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)CK1α (Casein kinase I alpha)CRBN (Cereblon)IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)
Beyond the preview
Go deeper on linvoseltamab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linvoseltamab + lenalidomide.